Proteintech, HebeCell to develop cancer immunotherapies

By The Science Advisory Board staff writers

November 12, 2020 -- Proteintech and HebeCell have announced a partnership to develop nanobody-based chimeric antigen receptors (nCARs) for cancer cellular immunotherapy use.

The nCAR technology will be used to develop induced pluripotent stem cells (iPSCs) -derived natural killer cells, according to the firms. Proteintech recently acquired ChromoTek, which augmented its nanobody development resources, while HebeCell holds intellectual property regarding natural killer cells.

New model could improve vaccine, immunotherapy design
A new model used to predict the outcomes of pathogen detection systems as a function of innate immunity may lead to more effective cancer immunotherapies...
Proteintech acquires ChromoTek
Proteintech, a German-based producer of antibodies, proteins, and immunoassays, has acquired ChromoTek, a manufacturer of camelid single-domain antibodies...
Canada orders 20M doses of Moderna COVID-19 vaccine
The Canadian government increased its confirmed order commitment to 20 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate.
Moderna, Vertex collaborate on gene editing therapies for cystic fibrosis
Moderna and Vertex Pharmaceuticals have entered a three-year research collaboration for the discovery and development of lipid nanoparticles and messenger...
Maps of natural killer cells offer insight into COVID-19 immune response
New research that sought to classify immune white blood cells, called natural killer cells, during COVID-19 infection revealed that certain cellular subtypes...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter